Do not stop Exelon Patch solely because dementia has reached a particular stage; FDA labeling sets no routine stopping stage. The prescriber should decide whether its benefits still outweigh its harms and supervise any discontinuation. Exelon Patch is a skin patch that delivers rivastigmine, a cholinesterase inhibitor used for dementia symptoms. Stopping may worsen thinking, daily function, or behavioral symptoms, while continuing can also cause significant side effects.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Is dementia severity a reason to stop?
- How can we tell whether it is helping?
- What might happen after discontinuation?
- Do side effects justify stopping?
- What should the safe plan cover?
Is dementia severity a reason to stop?
The FDA prescribing label indicates Exelon Patch for mild, moderate, and severe Alzheimer's dementia. It also covers mild-to-moderate Parkinson's disease dementia. It does not establish a stage when treatment should routinely end.
A shift from moderate to severe Alzheimer's dementia therefore does not automatically mean the patch has stopped being appropriate. The more useful question is whether this individual still appears to benefit without unacceptable harm. ask the prescriber:.
- Is the dementia diagnosis one for which the patch is indicated?
- Is progression alone driving this discussion?
- What individual evidence supports continuing or stopping?
- Have health changes altered the balance of benefit and risk?
How can we tell whether it is helping?
exelon Patch may help cognition and daily tasks over six to 12 months, but responses vary. Some people do not benefit, and the medicine does not cure Alzheimer's disease. The FDA label says an effective dose should continue only while therapeutic benefit persists.
Before making a decision, describe changes in concrete terms. Consider whether the person's thinking, daily activities, or behavior changed after starting the patch or after a dose change. Also ask whether apparent decline could obscure a smaller ongoing benefit. Useful questions include:.
- What benefit was the patch originally meant to provide?
- Which changes have caregivers actually observed?
- What would count as evidence that benefit persists?
- What outcomes will be monitored if treatment stops?
- When will the prescriber review the decision?
What might happen after discontinuation?
Stopping is not necessarily harmless. A Cochrane review found that discontinuing cholinesterase inhibitors may worsen cognition, function, or neuropsychiatric symptoms—changes involving behavior or mood—compared with continuing them. The evidence has important limits.
The seven reviewed trials included only people with Alzheimer's dementia, did not establish effects by dementia severity, and mostly provided low- or very-low-certainty evidence. Those findings cannot predict exactly what will happen to one person or establish the same effects in Parkinson's disease dementia. Ask what changes should trigger prompt reassessment and whether restarting would be considered if noticeable deterioration follows discontinuation. Agree on who will observe the person, what will be recorded, and when the prescriber wants an update.
Do side effects justify stopping?
Significant nausea, vomiting, diarrhea, appetite loss, or weight loss can justify interruption or reassessment. Risks rise with the dose, and prolonged vomiting or diarrhea can cause dehydration with serious consequences. Skin redness confined to the patch area is different from suspected allergic contact dermatitis.
According to the FDA safety instructions, the patch should be discontinued when a reaction spreads beyond its borders, becomes intense, or fails to improve within 48 hours after removal. If allergy is suspected, do not assume oral rivastigmine is a safe substitute. Switching to oral rivastigmine requires negative allergy testing and close medical supervision.
What should the safe plan cover?
Tell the prescriber exactly when the last patch was applied. If treatment has been stopped or missed for more than three days, FDA instructions call for restarting at 4.6 mg per 24 hours and increasing the dose again, rather than resuming the former dose. This reduces the risk of severe vomiting.
A medication review is also important. Rivastigmine can slow the heart rate and requires caution in people with heart-conduction disease. Concurrent beta-blockers, metoclopramide, cholinomimetics, or anticholinergics are not recommended. Bring a complete medication list and ask:.
- Should treatment stop immediately, or does the prescriber recommend another plan?
- What symptoms or functional changes should caregivers document?
- Who should be contacted if problems appear?
- If restarting becomes appropriate, which dose should be used?
- Could another medicine or health condition be increasing the risks?
